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Aim: The aim was to compare
 




F-FDG) PET and integrated 
PET/CT
 
in patients with primary, recurrent or metastatic 
ovarian cancer. 
Materials and methods. 21 women with ovarian cancer 
were evaluated. All patients had a integrated PET/CT 
scan. Localization, infiltration and uptake intensity of 
[
18
F]FDG were evaluated on PET and PET/CT. The 
certainty of localisation and characterisation was scored 
on a 3 point scale (L1 definite localisation; L2 probable 
localisation; L3 uncertain localisation; C1 benign; C2 
equivocal; C3 malignant). 
Results. PET scored as L1 54 lesions (44%), as L2 51 
(42%), and as L3 17 (14%). On the other hand, PET/CT 
scored as L1 120 lesions (98%), as L2 2 (2%), and none 
as L3. Thus PET/CT allowed a better localization in 54% 
of lesions. Moreover, PET scored as C1 25 lesions (20%), 
as C2 62 (51%), and as C3 35 (29%) . On the other hand, 
PET/CT scored as C1 57 lesions (47%), as C2 13 (11%), 
and as C3 52 (42%). Thus PET/CT allowed a sensible 
reduction in the number of equivocal lesions (40%). Even 
when patients were subgrouped on the basis of clinical 
stage of the disease, PET/CT was capable of better 
definition of the lesions either for localization and for 
characterization. 
Conclusions. In patients with ovarian cancer, PET/CT 
allows better anatomical localisation of pathologic uptake 
providing high accuracy for staging and restaging of 
ovarian cancer when compared with PET alone. 
KEY WORDS. Ovarian Cancer; 
18
F-FDG; PET/CT.
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INTRODUCTION 
Ovarian cancer is the third most common of all 
female reproductive system cancer in terms of 
frequency, but it determines 50% of deaths. 
Diagnosis of ovarian cancer is relatively late, while 
the use of ultrasound examination and tumoral 
markers dosage (eg. CA125) promotes early 
detection of cancer. 
Clinical stage is the most important prognostic factor 
in ovarian cancer. Actually, the overall five year 
survival rate is 80% for stage I, 50% for stage II, 
30% for stage III and less than 8% for stage IV (1). 
As a consequence a correct staging is relevant, and 
imaging plays an important role with a better 
accuracy of Computed Tomogaphy (CT) and 
Magnetic Resonance (MR) in advanced stages than 
ultrasound (2). 





F-FDG) may be used for 
diagnostis as well as for staging and re-staging of 
patients with ovarian cancers. The introduction of 
integrated PET/CT, allowing the visualization of 
either functional and morphological information on 
fused images, improved diagnostic significantly due 
to a reduction in False Positive and False Negative 
values.  
The aim of this study is to compare results acquired 
with FDG PET to integrated FDG PET/CT imaging 
technique in patients with ovarian cancer. 
 
MATERIALS AND METHODS 
Population. A total of 21 women with ovarian cancer 
(age range 29 - 80 years, mean 53 ± 14) constituted 
the study group. Two of them were in staging phase, 
12 in chemotherapeutical follow-up, 7 in post-
surgical stage. All have been staged according to the 
FIGO (International Federation of Gynecology and 
Obstetrics) stadiation as follows: 4 were at I stage, 1 
was at II stage, 5 were at III stage and 11 were at IV 
stage.  Tumour markers such as CA125, αFP and 
βHCG have been dosed: marker’s values were 
increased in 17 patients and were normal in 5 cases. 
(Table I).  
Image Acquisition. All patients fasted for 8 hours 
before imaging. PET/CT was obtained on a 
commercial PET/CT scanner (Discovery LS; GE 
Milwaukee, WI, USA), which combines an Advance 
NXi PET scanner and a Light Speed Plus four row 
MDCT system. In all studies, PET/CT imaging was 
acquired 60 minutes after intravenous administration 
of 370 – 444 MBq of 
18
F-FDG. MDCT (pitch 1.5; 
120 mAs; 120 kVp) was performed without 
intravenous and/or oral contrast medium as part of 
the PET/CT scan. PET scanning was subsequently 
performed with 4 minutes per bed position and six to 
eight bed positions per patient, depending on patient 
height. Raw CT data were reconstructed into 
transverse images with a 4.25-mm section thickness. 
Sagittal and coronal CT images were generated by 
reconstruction of the transverse data. Raw PET data 
were reconstructed with and without attenuation 
correction into transverse, sagittal, and coronal 
images. Attenuation correction was based on the CT 
attenuation coefficients, which were determined by 
iterative reconstruction. Blood glucose level was 
determined in all patients before 
18
F-FDG 
administration and a cut-off value of less than 140 
mg/dL was considered appropriate to perform 
examination.  
Data analysis. Two nuclear medicine physicians, 
unaware of the patients’ clinical history, blindly 
examined PET images, evaluating localization and 
characterization and compared them to co-registered 
PET/CT images. Maximum standardized uptake 
values (SUVmax) were determined by using vendor-
provided software (Volumetrix for PET-CT; GE 
Healthcare) on PET scans. Region of interest 
diameter was set at 1 cm. SUVmax was body weight 
corrected. 
Anatomical localization and lesion characterization 
were the two parameters used for the evaluation of 
each lesion. For both parameters a three point  score 
was used:  L1 (definite localization), L2 (probable 
localization), L3 (uncertain localization); C1 
(benign), C2 (equivocal), C3 (malignant) (Table II). 
Weighted Kappa Statistical Analysis for both PET 
and PET/CT to evaluate the interobserver variability 
in the assessment of the localization and the 
characterization (3). 
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RESULTS 
Both PET and PET/CT identified 122 lesions in 21 
patients. Of the 122 lesions PET scored 54 lesions 
(44%) as L1, 51 lesions (42%) as L2, 17 lesions 
(14%) as L3. PET/CT scored 120 lesions (98%) as 
L1, 2 lesions (2%) as L2 and 0 lesions as L3. Table 
III shows the comparison between the two imaging 
methods. PET/CT allowed a better localization in a 
large number of lesions (54%). 
Of the 122 lesions PET characterized 25 lesions (20 
%) as C1, 62 lesions (51 %) as C2, 35 lesions (29 %) 
as C3. PET/CT characterized 57 lesions (47%) as C1, 
13 lesions (11 %) as C2, 52 lesions (42%) as C3. 
Table IV shows the comparison between the two 
imaging methods. PET/CT allowed a sensible 
reduction (40%) in the number of equivocal lesions.  
PET/CT improves the localization of lesions in 60% 
of patients with stage I and II ovarian cancer and the 
characterization with a 43% reduction of uncertain 
lesions (Table V). PET/CT improves of 40% the 
localization and of 46% the characterization in 
patients with III stage ovarian cancer and improves 
of 60% the localization and of 32% the 
characterization in patients with IV stage (Tables VI 
and VII).  
Concordance of PET for localization was 89% 
(109/122) k = 0.82; Concordance for characterization 
was 90% (110/122) k = 0.84; the level of 
concordance of PET/CT for localization was 100% 
(122/122) k = 1.0; the level of concordance for 
characterization was 99% (121/122) k = 0.99.  
 
DISCUSSION 
 The results of the present study show that 
PET/CT allows a better localization in 54% of 
lesions and a better characterization of tracer uptake 
in 40% of lesions with an higher interoperator 
reproducibility than PET. The role of 
18
F-FDG -PET 
in diagnosis and staging of primitive ovarian cancer 
is controversial. Older studies (4, 5) showed a 
sensitivity of 83-86% and a specificity of 54-86%. 
Rieber et al. (6) examined the role of FDG-PET in 
preoperative diagnosis of 103 patients with 
sensitivity, specificity and diagnostic accuracy values 
of 58%, 78% and 76% respectively. Values obtained 
with other methods such as MR, transvaginal 
sonography and histologic findings were: sensitivity  
83%, 92% and 92%; specificity 84%, 59% and 84%; 
diagnostic accuracy 83%, 63% and 85%, 
respectively. More recently Fuccio et al. concluded 
that F-18 FDG PET/CT represents an important 
method in addition to other imaging modalities 
(transvaginal ultrasound-, and contrast-enhanced 
computed tomography) in the characterization of 
adnexal masses and in the staging of ovarian cancer 
patients, particularly in assessing the presence of 
extra-abdominal metastatic spread (7). In addition, 
the low value of FDG PET sensitivity is related to 
the high percentage of low malignity cancers and to 
early cancers compared to the high sensitivity of 
previous studies that analyzed advanced ovarian 
cancers. 
Zinny et al. (8) studied the role of FDG-PET in the 
diagnosis of recurrent ovarian cancer in 106 patients 
under follow-up selected for secondary cytoreductive 
surgery and chemotherapy. Overall sensitivity of 
83% and specificity of 83% were observed. 
Moreover, sensitivity was 94% in patients with 
clinical suspicion of disease, compared to 65% in 
patients considered clinically free. Sari et all. 
Showed that PET/CT is a beneficial method for 
detection of the recurrence, in patients with increased 
serum CA 125 level and negative CT findings or 
with normal CA 125 level and recurrence detected by 
CT which was performed due to clinical 
symptoms(9). 
PET itself gives few informations on anatomic 
localization of lesions, making difficult to 
discriminate between areas of pathological uptake 
and physiological distribution of tracer (10, 11).The 
hybrid PET/CT system produces multimodal images 
with anatomical morphological outline useful for a 
better spatial localization of tracer distribution 
Bristow reported a PET/CT accuracy of 81,8% in 
discriminating recurrent ovarian cancer (>1 cm) and 
a 83,3 % sensitivity (12). Sironi study analyzed the 
possible role of PET/CT in the evaluation of 
recurrent ovarian cancer and reported an high 
positive predictive value (89%) and a low negative 
predictive value (57%) (13). 
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Detection and exact localization of recurrent lesions 
are critical for guiding management and determining 
the proper therapeutic approach, which may prolong 
survival. Fluorine 18 fluorodeoxyglucose positron 
emission tomography (PET) combined with CT is 
useful for detection of recurrent or residual ovarian 
cancer and for monitoring response to therapy. 
However, PET/CT may yield false-negative results 
in patients with small, necrotic, mucinous, cystic, or 
low-grade tumors. In addition, in the posttherapy 
setting, inflammatory and infectious processes may 
lead to false-positive PET/CT results. Despite these 
drawbacks, PET/CT is superior to CT and MR 
imaging for depiction of recurrent disease. (14) 
In the present study PET/CT showen a remarkably 
low percentage of uncertain localization (2% of 
lesions). In addition, characterization of lesions was 
improved by PET/CT. Thus, PET/CT not only allows 
a better localization of lesions but also plays a role in 
characterization. The improvement in both lesion 
localization and characterization was consistent in all 
stages of disease. These findings are in agreement 
with previously reported data (15). Moreover, recent 
studies demonstrated that FDG-PET/CT is more 
accurate than CT and MR in the detection of lymph 





PET/CT improves the anatomical localization of 
lesions and the related characterization with a strong 
decrease of lesions considered uncertain and it shows 
an  high reproducibility. Integrated FDG-PET/CT 
can be successfully used for diagnosis, staging, 
restaging, therapy monitoring and prognostic 
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a: abnormal marker value 
n: normal marker value 
# AGE HISTOLOGY STAGE SURGERY CHEMOTHERAPY MARKERS 
1 53 endometrioid cancer IV yes yes Ca 125(a) 
2 69 tubaric cancer II A yes yes Ca 125(a 
3 50 serous cancer IV yes yes Ca125 (a) 
4 53 clear cell cancer IA yes yes Ca125 (n) 
5 72 ovarian cancer III yes yes Ca125 (n) 
6 73 serous ovarian cancer IA yes yes Ca125 (a) 
7 33 germ cell ovarian cancer III yes yes αFP (n) 
8 50 ovarian cancer IV yes yes Ca 125(a) 
9 51 ovarian cancer IV yes yes Ca125 (n) 
10 51 ovarian cancer IV yes yes Ca125 (n) 
11 29 choriocarcinoma IV yes yes βHCG a) 
12 67 serous mucinous ovarian cancer IA yes yes Ca125 (a) 
13 80 mucinous ovarian cancer I yes no Ca125 (a) 
14 58 papillary serous ovarian cancer III yes no Ca125 (a) 
15 74 serous cancer IV yes no Ca125 (a) 
16 65 papillary serous ovarian cancer III yes yes Ca125 (a) 
17 66 endometrioid cancer IV yes yes Ca125 (a) 
18 50 mucinous ovarian cancer IV no no Ca125 (a) 
19 43 mucinous ovarian cancer IV no no Ca125 (a) 
20 72 ovarian cancer III yes no Ca125 (a) 
21 62 ovarian cancer IV yes no Ca125 (a) 
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TABLE II 
Localization and Characterization Scores 





C1 (benign)  






C2 (equivocal)  
SUV ≥ 2.0 but < 2.5 
L3 (uncertain): 
localization possible 
only for large 
topographic areas 
C3 (malignant)  
SUV ≥ 2.5 
 
TABLE III 














L2 probable 51 
(42%9 
2 (2%) -40% 
















+ 27 % 













Stage I and II patients: PET and PET/CT 









L1 definite 12 (40%) 30 
(100%) 
+ 60 % 
L2 probable 18 (60%) 0 -60% 
L3 uncertain 0 0 0 
characterization  
C1 benign 12 (40%) 24(80%) +40% 
C2 
equivocal 
18 (60%) 5 (17%) - 43% 
C3 
malignant 
0 1(3%) +3% 
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TABLE VI 
Stage III patients: PET and PET/CT 
(Patients= 5, Lesions=  35) 
 





L1 definite 19 (54%) 33 (94%) + 40 % 
L2 probable 15 (43%) 2 (6%) - 37% 
L3 uncertain 1 (3%) 0 - 3% 
characterization  
C1 benign 4 (11%) 14 (40%) + 29% 
C2 
equivocal 
21 (60%) 5 (14%) - 46 % 
C3 
malignant 





Stage IV patients: PET and PET/CT 
(Patients= 11, Lesions=  57) 
 





L1 definite 10 (18%) 21 (37%) + 19% 
L2 probable 23 (40%) 5 (8%) - 32 % 
L3 uncertain 24 (42%) 31 (55%) + 13% 
characterization score 
C1 benign 10 (18%) 21 (37%) + 19% 
C2 equivocal 23 (40%) 5 (8%) - 32 % 
C3 malignant 24 (42%) 31 (55%) + 13% 
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